Home / Market News / $STLN

$STLN news and market catalysts

The 3 most recent market catalysts affecting $STLN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

3 catalysts 2 high impact 2 bullish 0 bearish Healthcare
Nov 5, 2026 Corporate Catalyst Neutral Impact 80
Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year Guidance
Starling Oncology announced its Q3 2026 financial results, highlighting a significant 44% year-over-year increase in specialty pharmacy revenue to $109 million, alongside a 24% gro…
Oct 14, 2026 Corporate Catalyst Bullish Impact 60
Needham Maintains Buy on Starling Oncology, Raises Price Target to $9
Needham analyst Matthew Shea maintained a 'Buy' rating on Starling Oncology (STLN) and raised the price target from $7 to $9. This upgrade signals increased confidence from a reput…
Aug 7, 2026 Corporate Catalyst Bullish Impact 92
Starling Oncology Q2 EPS $(0.08) Up From $(0.15) YoY, Sales $161.282M Up From $119.802M YoY
Starling Oncology (STLN) announced its Q2 financial results, reporting a narrower loss per share of $(0.08) compared to $(0.15) in the prior year, representing a 46.67% improvement…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.